NATCO Announces Launch of its Everolimus Tablets, 1 mg, (generic of Zortress®)

Hyderabad: NATCO Pharma Limited announces launch of Everolimus tablets 1mg, a generic version of Zortress® by Novartis, under the therapeutic class of immunosuppressant. NATCO’s marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, plans to launch the product immediately in the U.S. market. Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation. Breckenridge previously launched its Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blisters launched in July 2021 and bottles launched in June 2023. *Safe Harbor Statement Please visit www.breckenridgepharma.com for full prescribing information including warnings, precautions, and adverse reactions. All brand names and trademarks are the property of their respective owners

The release as fetched from its publisher. natcopharma.co.in ↗